Supplementary Data from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors

Authors :: Jason J. Luke
Jedd D. Wolchok
Taha Merghoub
Cynthia A. Sirard
Diane Piper
Lianna Sifferlen
Phillip Wong
Aliya Holland
Jingjing Qi
Walter Newman
Olivier Rixe
David Bajor
Todd Bauer
Takami Sato
Girish S. Naik
Hong Wang
Roberta Zappasodi
Diwakar Davar
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Supplementary Data from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors

Full Text Access

Tools